English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background and Design: Pentraxin 3 (PTX 3), an acute phase protein, plays an important role in activation of innate immunity and in the regulation of inflammatory reactions. Thus, considering the importance of PTX 3 in immune and inflammatory responses, it has been\udsuggested that PTX 3 may play a role in the pathogenesis of psoriasis. The aim of this study was to evaluate plasma PTX 3 levels in patients with psoriasis and their relationship with the disease severity and the effect of narrowband ultraviolet B (nbUVB) therapy on PTX 3 levels.\udMaterials and Methods: The study comprised 40 patients with psoriasis and 88 age-and sex-matched healthy controls. Dermatological examinations and psoriasis area severity index (PASI) were performed. The patients received 20 courses of nbUVB therapy with a mean value\udof 13 joule/cm2. The efficacy of nbUVB was evaluated using PASI scores. Plasma PTX 3 levels in the patient group were measured before and after therapy by sandwich enzyme-linked immunosorbent assay in patients with the diagnosis of psoriasis and were compared with that in the control group.\udResults: The mean plasma PTX3 level in the patient group (1.24±0.83) was statistically significantly increased compared to that in the control group (0.55±0.26) (p<0.05). A statistically significant decrease in PASI scores were observed after nbUVB therapy (p<0.05). The mean pretreatment plasma PTX 3 level in patients with psoriasis (1.24±0.83) statistically significantly decreased after treatment (0.84±0.62) (p<0.05).Furthermore, the mean post-treatment plasma PTX 3 level in the patient group (0.84±0.62) was significantly higher than in healthy controls (0.55±0.62) (p<0.05).\udThere was no relationship of plasma PTX 3 levels with disease severity, family history, nail involvement, gender, age, and duration of disease (p>0.05).\udConclusion: We found that plasma PTX3 levels that are increased in patients with psoriasis were not correlated with disease severity and that they significantly decreased after nbUVB therapy

Pentraxin 3 levels in psoriasis, their relationship with disease severity and the efficacy of narrow-band ultraviolet B therapy